- In May 2026, Maximus, Inc. entered into a second amendment to its Amended and Restated Credit Agreement, securing an additional US$325,000,000 in Tranche B-1 term loans with terms matching its existing term B facilities.
- The new borrowing, earmarked for revolver repayment, share repurchases, working capital, and related fees, highlights Maximus’ active use of leverage to fund capital returns while maintaining liquidity.
- We’ll now examine how Maximus’ expanded term loan capacity and planned share repurchases affect the company’s existing investment narrative and risk profile.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
Maximus Investment Narrative Recap
To own Maximus, you need to believe that governments will keep outsourcing complex, highly regulated citizen services and that Maximus can keep earning attractive returns on that work. The new US$325,000,000 Tranche B-1 term loan modestly tilts the story toward higher financial leverage and capital returns, but does not fundamentally change the near term catalyst of contract execution or the key risk of technology and automation disrupting traditional services.
This new borrowing links directly to Maximus’ recent share repurchase activity, supported by its ongoing dividend of US$0.33 per share in early 2026. Together, the buybacks and expanded term loans point to a more aggressive capital return posture at a time when earnings guidance for fiscal 2026 remains at US$5.2 billion to US$5.35 billion in revenue, which could sharpen both the upside and the risk around future cash generation.
Yet investors should be aware that higher leverage can amplify the impact of any contract or volume shock on...
Read the full narrative on Maximus (it's free!)
Maximus' narrative projects $5.8 billion revenue and $498.1 million earnings by 2029. This requires 2.8% yearly revenue growth and a roughly $126.3 million earnings increase from $371.8 million today.
Uncover how Maximus' forecasts yield a $110.00 fair value, a 79% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue could reach about US$5.9 billion and earnings nearly US$493 million by 2029, so this fresh debt funded buyback capacity may either reinforce that upbeat view on capital efficiency or heighten concerns about balance sheet risk, depending on how you weigh the potential contract renewal and budget headwinds they were also flagging.
Explore 2 other fair value estimates on Maximus - why the stock might be worth over 4x more than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Maximus research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Maximus research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Maximus' overall financial health at a glance.
No Opportunity In Maximus?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
- AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com